Oric Pharmaceuticals, Inc. (ORIC) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$12.85

From 52W high−12.70%

Volume3.05M

Market cap$1.33B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$12.85

From 52W high

−12.70%

Volume

3.05M

Market cap

$1.33B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−7.4x

P/E (TTM)

—

RSI (14)

49.9

MomentumView details →

1D Return

−0.70%

YTD Return

+55.75%

SummaryUpdated Jun 1, 2026

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in South San Francisco, California. The company went public in April 2020 and focuses on discovering and developing precision cancer therapies that target specific resistance mechanisms in oncology. ORIC operates as a research-driven organization that aims to overcome the challenges patients face when their cancers become resistant to existing treatments, including both chemotherapy and newer immunotherapy approaches.

Ask drillr about Oric Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−7.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

3.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−36.81%

ROA (TTM)

−34.68%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+28.57%

FCF YoY

+7.52%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+19.67%

EBITDA YoY

−2.29%

MomentumView details →

1D Return

−0.70%

YTD Return

+55.75%

1Y Return

+20.64%

RSI (14)

49.9

vs 50D SMA

+2.21%

vs 200D SMA

+19.36%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

13.19x

Quick Ratio

13.19x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.38

EPS Surprise

−5.75%

Beats (12Q)

7/12

Next Q EPS Est

−$0.38

Avg Surprise (4Q)

1.50%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−140.35M

Op. CF (TTM)

−111.64M

Next earningsNov 12, 2026 →

Latest newsMore news →

ORIC Pharmaceuticals initiated the Himalayas-1 global Phase 3 trial of rinzimetostat in combination with darolutamide for mCRPC patients previously treated with abiraterone.68d ago

Similar companies

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.02566.HK ImmuneOnco Biopharmaceuticals (Shanghai) Inc.01541.HK Omeros CorporationOMER Immatics N.V.IMTX Zhaoke Ophthalmology Limited06622.HK LB Pharmaceuticals Inc Common StockLBRX Find similar companies →

Latest newsMore news →

ORIC Pharmaceuticals granted 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees on August 3, 2026, as inducement grants under Nasdaq Listing Rule 5635(c)(4).44d ago ORIC Pharmaceuticals initiated the Himalayas-1 global Phase 3 trial of rinzimetostat in combination with darolutamide for mCRPC patients previously treated with abiraterone.68d ago